- Home
- BMR vs PRLD Comparison
BMR vs PRLD Comparison
Compare BMR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- PRLD
- Stock Information
- Founded
- BMR 2009
- PRLD 2016
- Country
- BMR Israel
- PRLD United States
- Employees
- BMR N/A
- PRLD N/A
- Industry
- BMR Computer Software: Prepackaged Software
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BMR Technology
- PRLD Health Care
- Exchange
- BMR Nasdaq
- PRLD Nasdaq
- Market Cap
- BMR 48.5M
- PRLD 44.0M
- IPO Year
- BMR 2023
- PRLD 2020
- Fundamental
- Price
- BMR $2.78
- PRLD $1.22
- Analyst Decision
- BMR
- PRLD Strong Buy
- Analyst Count
- BMR 0
- PRLD 3
- Target Price
- BMR N/A
- PRLD $4.00
- AVG Volume (30 Days)
- BMR 511.4K
- PRLD 222.4K
- Earning Date
- BMR 08-13-2025
- PRLD 08-14-2025
- Dividend Yield
- BMR N/A
- PRLD N/A
- EPS Growth
- BMR N/A
- PRLD N/A
- EPS
- BMR N/A
- PRLD N/A
- Revenue
- BMR $3,131,000.00
- PRLD $7,000,000.00
- Revenue This Year
- BMR $21.21
- PRLD N/A
- Revenue Next Year
- BMR N/A
- PRLD N/A
- P/E Ratio
- BMR N/A
- PRLD N/A
- Revenue Growth
- BMR 5.96
- PRLD N/A
- 52 Week Low
- BMR $1.86
- PRLD $0.61
- 52 Week High
- BMR $6.59
- PRLD $5.53
- Technical
- Relative Strength Index (RSI)
- BMR 40.58
- PRLD 61.77
- Support Level
- BMR $2.69
- PRLD $1.10
- Resistance Level
- BMR $3.59
- PRLD $1.33
- Average True Range (ATR)
- BMR 0.29
- PRLD 0.16
- MACD
- BMR -0.03
- PRLD 0.02
- Stochastic Oscillator
- BMR 7.76
- PRLD 78.43
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.